PMS5 Benefit-Risk Analysis of Adalimumab and Alternative Treatments for Moderate-to-Severe Rheumatoid Arthritis
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.1360
https://www.valueinhealthjournal.com/article/S1098-3015(12)03073-2/fulltext
Title :
PMS5 Benefit-Risk Analysis of Adalimumab and Alternative Treatments for Moderate-to-Severe Rheumatoid Arthritis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)03073-2&doi=10.1016/j.jval.2012.08.1360
First page :
A439
Section Title :
Muscular-Skeletal Disorders
Open access? :
No
Section Order :
857